Browse the evidence

Finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduces hospital admissions for heart failure and end-stage kidney disease, and decreases mortality in Type 2 Diabetes patients with Chronic Kidney Disease (CKD).

If you have Type 2 Diabetes and Chronic Kidney Disease, ask about Finerenone. It is a non-steroidal medication that helps protect your heart and kidneys, reducing the risk of hospitalization for heart failure and kidney failure, though it requires monitoring for potassium levels.

Sustained administration of PYY(3-36) protects against high-fat diet-induced pancreatic and intestinal morphological deterioration by restoring ileal GLP-1 content and reducing beta-cell turnover.

This research suggests that maintaining healthy gut hormone levels, specifically GLP-1, is crucial for protecting pancreatic health during high-fat diets. While this study used direct PYY(3-36) injection, it supports the broader concept that enhancing incretin activity (like GLP-1) can protect pancreatic structure and function. For individuals, this underscores the importance of dietary patterns that support natural GLP-1 secretion and the potential therapeutic value of incretin-based interventions for metabolic health.

GLP-1 receptor agonists (GLP-1 RAs) are primarily prescribed as anti-diabetic medications (ADMs) rather than anti-obesity medications (AOMs), with 71.8% of first-time prescriptions designated for diabetes management and only 28.2% for obesity.

While GLP-1 medications like semaglutide and tirzepatide are famous for weight loss, the vast majority of prescriptions (over 70%) are for treating Type 2 Diabetes. If you are seeking these medications for weight loss, you may face higher costs and insurance hurdles because they are not primarily covered for obesity in many cases.

Downregulation of the transcription factor NR4A3 in human skeletal muscle, mimicking physical inactivity, impairs glucose oxidation and protein synthesis while increasing fatty acid oxidation and lactate production, leading to muscle atrophy.

Physical inactivity actively suppresses a key protein (NR4A3) in your muscles, which shifts your metabolism away from burning glucose and toward making lactate, while simultaneously shutting down muscle building signals. This molecular change is a primary driver of muscle loss during sedentary periods. While this study was done on cells, it suggests that maintaining NR4A3 levels (e.g., through movement) is crucial for preserving muscle mass and metabolic health, and future therapies might target this pathway.

Dual GLP1R/GIPR agonists achieve superior glucose lowering and weight reduction compared to single GLP1R agonists through specific engagement of pancreatic islet cells (beta, alpha, delta) and circumventricular organ neurons, rather than through enhanced brain penetration.

Dual GLP1/GIP agonists work better than single GLP1 drugs because they target specific cells in the pancreas (beta, alpha, delta) and specific neurons in the brain's edge (circumventricular organs), not because they penetrate the brain deeper. This targeted engagement drives superior glucose and weight outcomes.

Dual GLP1R/GIPR agonists label pancreatic beta, alpha, and delta cells with varying intensity (beta > alpha = delta), engaging distinct receptor nanodomains that differ from those targeted by single agonists.

Dual agonists affect multiple hormone-secreting cells in the pancreas, with the strongest effect on insulin-secreting beta cells, followed by glucagon-secreting alpha and somatostatin-secreting delta cells.

A specific missense variant in the GIP receptor (GIPR, rs1800437, p.Glu354Gln) is associated with an increased risk of vomiting in patients treated with tirzepatide, but not semaglutide.

If you are taking tirzepatide (Mounjaro/Zepbound), your genetics can influence your risk of vomiting. A specific variant in the GIP receptor (rs1800437) is linked to a higher risk of vomiting. This is specific to tirzepatide because it targets both GLP-1 and GIP receptors. If you experience severe vomiting, discussing your genetic history or considering alternative therapies might be beneficial, as this genetic factor does not affect semaglutide users.

Recent safety data from the SELECT trial indicates a higher incidence of hip and pelvic fractures in female patients and those aged 75+ taking semaglutide 2.4 mg weekly compared to placebo.

If you are over 75 or a postmenopausal woman taking semaglutide for heart health, be aware that your risk of hip or pelvic fractures may be slightly higher than if you were not taking the drug. This risk is likely linked to the weight and muscle loss. Ensure you are doing strength training, getting enough calcium/Vitamin D, and discussing bone density scans (DEXA) with your doctor.

Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, produces significant weight loss in patients with specific genetic obesity disorders (POMC, LEPR, or PCSK1 deficiency).

Setmelanotide is an FDA-approved treatment for obesity caused by specific genetic mutations (POMC, LEPR, or PCSK1 deficiency). In clinical trials, it led to significant weight loss (up to 51 kg over 42 weeks) in patients with these conditions. It is not for general obesity but targets the underlying hormonal pathway affected by these genetic disorders.

Pharmacologic activation of GIP and GLP-1 receptors rapidly inhibits AgRP neurons, and this neural inhibition contributes to the appetite-suppressing effects of incretin-based obesity therapies.

Incretin-based medications (like semaglutide and tirzepatide) work in part by shutting down hunger-promoting brain cells (AgRP neurons). This mechanism is driven by both GIP and GLP-1 pathways, with dual-action drugs being more effective than single-action ones. This neural inhibition helps explain why these drugs successfully reduce food intake, even in individuals with obesity.

Genetically modeled dual GIPR/GLP1R agonism reduces binge drinking frequency and the risk of heavy drinking with psychiatric comorbidities.

Genetic evidence suggests that activating GLP-1 and GIP receptors (via drugs like semaglutide or tirzepatide) can reduce binge drinking and heavy drinking, especially in those with psychiatric comorbidities. This effect appears independent of general alcohol consumption (drinks per week), suggesting a specific impact on high-risk drinking patterns.

Higher adiposity (BMI) is positively associated with increased striatal dopamine tone in humans, as indicated by the differential displacement of low-affinity D2 receptor tracers.

This research suggests that higher body weight is associated with higher baseline (tonic) dopamine levels in the brain's reward centers. This may alter how rewarding food feels, potentially contributing to overeating. While this doesn't provide a direct 'fix,' it highlights that obesity is a neurochemical state, not just a willpower failure. Interventions might need to account for this altered reward sensitivity.

Co-ingesting cluster dextrin (CDX) with protein after resistance exercise does not increase myofibrillar protein synthesis or total amino acid availability compared to glucose, despite enhancing intramuscular mTORC1 signaling.

If you are eating protein after resistance training, switching from glucose to cluster dextrin will not help you build more muscle. While CDX might trigger slightly higher signaling markers (mTORC1), it does not translate to actual muscle protein synthesis gains compared to regular glucose. Stick to what works and costs less.

Genetic deletion or specific knockdown of the mitochondrial protein MCJ (DnaJC15) in brown adipose tissue promotes thermogenesis and protects against diet-induced obesity through a UCP1-independent mechanism mediated by eIF2α signaling.

This research suggests that targeting the MCJ protein in fat cells could help the body burn more energy and resist weight gain, even without relying on the classic 'uncoupling' protein UCP1. While this is currently a genetic finding in mice, it points to potential future therapies for obesity that enhance metabolic rate through mitochondrial stress responses.

Resmetirom, a thyroid hormone receptor beta (THRβ) agonist, is the first FDA-approved drug specifically for MASH, demonstrating significant improvement in both steatohepatitis and fibrosis in patients with advanced liver fibrosis.

Resmetirom is the first FDA-approved drug specifically for MASH. It works by targeting thyroid hormone receptors in the liver to reduce fat and inflammation. It is particularly effective for patients with advanced fibrosis, but note that about 70% of patients may not respond. It is a valuable option for those who do not respond to GLP-1RAs or SGLT2-is, or who need liver-specific treatment.

Incretin therapies are associated with gastrointestinal side effects and potential risks of gallstone disease and pancreatitis, requiring careful patient selection and monitoring, particularly in those with a history of these conditions.

While incretin therapies are effective for MASH, patients should be aware of common side effects like nausea and potential risks like gallstones or pancreatitis. These risks can be managed with slow dose titration, dietary adjustments, and regular monitoring, making the therapy safe for most patients when used appropriately.

Higher plasma levels of the specific nephronectin (NPNT) splice isoform, driven by increased body fat mass, causally increase the risk of severe COVID-19 and hospitalization.

If you have higher body fat mass, your body produces more of a specific protein called NPNT (specifically a splice isoform), which increases your risk of severe COVID-19. Reducing body fat mass and increasing fat-free mass through diet and exercise can lower these NPNT levels, thereby reducing your risk of severe outcomes from COVID-19.

Lower adipose NPR-C mRNA expression and higher NPR-A mRNA expression after weight loss predict better long-term weight maintenance and improved insulin sensitivity, independent of the weight maintenance intervention.

Your body's molecular response to weight loss (specifically the ANP system in fat tissue) may predict how well you maintain your weight and insulin sensitivity long-term. While you cannot change this directly, it suggests that personalized monitoring might be needed for those with less favorable molecular profiles.

Setmelanotide, an MC4R agonist, significantly reduces hunger and improves health-related quality of life in patients with POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome (BBS).

If you or your child has a confirmed diagnosis of POMC, LEPR, or BBS-related obesity, standard diet and exercise plans are unlikely to resolve the insatiable hunger (hyperphagia) because they don't fix the underlying genetic signaling error. Setmelanotide is an approved targeted therapy that directly addresses this mechanism, significantly reducing hunger scores and improving quality of life in clinical trials. Consult a specialist in rare metabolic disorders to determine eligibility.

Leptin replacement therapy is effective for reducing hunger and weight in patients with congenital leptin deficiency (homozygous LEP variants) but is ineffective in patients with defects downstream of the leptin receptor (e.g., POMC, PC1/3, MC4R deficiencies).

Leptin injections are highly effective for the rare condition of congenital leptin deficiency, significantly reducing hunger and weight. However, they are useless for patients with other genetic causes of obesity (like POMC or MC4R defects) because the body's ability to respond to leptin is broken downstream. Genetic testing is essential before considering this therapy.

Activation of the Area Postrema (AP) by GLP-1R agonists induces aversion (nausea) but is not necessary for appetite suppression, which is mediated by other brainstem regions like the Nucleus Tractus Solitarius (NTS).

Current GLP-1 drugs cause nausea by activating the Area Postrema in the brain, but weight loss is achieved by activating other brainstem areas (NTS). This separation suggests future drugs could be designed to minimize nausea while maintaining weight loss benefits.

Bariatric surgery (RYGB, VSG) and GLP-1R agonists share common neural targets in the brainstem (NTS, lPBN, CeA) and hypothalamus, suggesting overlapping mechanisms of action despite different peripheral origins.

Bariatric surgery and GLP-1 medications both work by activating specific brain pathways that reduce hunger and food intake. This shared mechanism explains why both are effective for severe obesity, even though one is surgical and the other is pharmacological.

Inhibiting Gs signaling specifically in K cells reduces plasma GIP levels and worsens glucose tolerance after refeeding.

This finding highlights that the natural Gs-mediated signaling in gut K cells is essential for maintaining normal blood sugar levels after eating. Disrupting this specific pathway impairs the body's ability to manage glucose spikes.

Elevated plasma levels of COL6A3-derived endotrophin, driven by increased body mass index (BMI), causally mediate an increased risk of coronary artery disease (CAD).

This research highlights that high body fat increases a specific protein fragment called endotrophin, which directly contributes to heart disease risk. The good news is that reducing body fat lowers these levels, suggesting that weight management strategies are effective not just for general health, but specifically for mitigating this biological pathway to heart disease.